PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

Smoking Cessation Clinical Trial

— PARQuit  

Official title:

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03950427
• Other study ID #: T29IP0235
• Secondary ID: 22637NCI-2022-02
• Status: Recruiting
• Phase: Phase 4
• Start date: July 8, 2019
• Est. completion date: July 1, 2025

Study information

• Verified date: September 2023
• Source: University of California, San Francisco
• Contact: Heather Leutwyler, PhD
• Phone: 415-514-1524
• Email: heather.leutwyler[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a research study about a smoking cessation program tailored for adults with serious mental illness (SMI). The program uses a Videogame-based Physical (VIP) activity, smoking cessation counseling, and medication (bupropion),

Description:

The purpose of this study is to learn more about how adults with serious mental illness respond to a smoking cessation program combining a game-based Physical activity, counseling for smoking cessation, and a medication (bupropion or NRT) for smoking cessation.

Study participants will receive counseling to quit smoking and a medication to help decrease cravings and withdrawal. Additionally, participants will be randomly selected to participate in either a game-based physical activity group or a game group where the participants sit to play the games.

Participants will be in this study for 12 weeks total. There are 3 assessment visits (2 hours each) at the beginning of the study, 6 weeks after starting, and at the end of the 12 weeks. There will be 8 30- minute counseling sessions during the 12 weeks. The hour-long videogame groups will be held 3 times a week for 12 weeks (36 sessions). Upon completion of the 12-week program, there will be a 1-2 hour group interview. The total time commitment is 48 hours over the course of the 12-week study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A diagnosis of a SMI*

• 18 years and older

• Smoking at least five cigarettes per day for the past 6 months

• Willingness to set a quit date

• Not currently taking bupropion or using nicotine replacement therapy (NRT)

• Current participant in the residential or day treatment program at a Progress Foundation program with the intention to continue in the residential or day treatment program for at least the 12 week intervention period

• Capacity to consent.

• SMI is characterized by the American Psychological Association as distinct conditions that require routine management, produce functional impairment, and interfere with quality of life. Individuals that typically meet the criteria of SMI have illnesses that include schizophrenia, schizoaffective disorder, psychotic disorders, major depressive disorders, bipolar disorders, and borderline personality disorder.

Exclusion Criteria:

• Currently pregnant or breastfeeding

• Diagnosis of seizure disorder, history of anorexia/bulimia, undergoing abrupt discontinuation of ethanol or sedatives, other conditions that increase seizure risk (e.g., arteriovenous malformation (AVM), severe head injury, central nervous system (CNS) tumor)

• use of Monoamine oxidase (MAO) inhibitors (concurrently or within 14 days of discontinuing either bupropion or the MAO inhibitor)

• Planning to become pregnant during the study period

• Previous participation in the videogame-based physical activity intervention.

• Known medical conditions or other physical problems that need special attention in an exercise program (e.g. prior myocardial infarction, uncontrolled hypertension, history of angioplasty, history of angina, use of nitroglycerin to treat angina)

Related Conditions & MeSH terms

• Mental Disorders
• Mental Illness
• Smoking Cessation
• Smoking, Tobacco
• Tobacco Use Disorder

Intervention

Behavioral:
• Videogame-based physical activity
videogame-based physical activity
• sedentary videogame
sedentary videogame

Drug:
• Bupropion
Bupropion

Behavioral:
• Counseling
Counseling for smoking cessation

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Tobacco Related Disease Research Program

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total number of videogame sessions attended	Feasibility will be measured with a total count of sessions attended. The graduate student researcher (GSR) will document participant attendance.	12-weeks
Primary	Total minutes of videogame sessions attended	Feasibility will be measured with a sum of minutes attended. The GSR will monitor and document the times when participants enter and leave the sessions.	12-weeks
Primary	Week-6 Self-report acceptability rankings of the videogames	This internally developed acceptability questionnaire has 7 questions. Three questions use a 1 to 5 scale with 1 indicating least acceptable and 5 indicating most acceptable, for a possible total range of 3-15. The remaining open-ended questions are scored using qualitative thematic analysis.	administered at week 6
Primary	Week-12 Self-report acceptability rankings of the videogames -week 12	This internally developed acceptability questionnaire has 7 questions. Three questions use a 1 to 5 scale with 1 indicating least acceptable and 5 indicating most acceptable, for a possible total range of 3-15. The remaining open-ended questions are scored using qualitative thematic analysis. Used to measure change from week-6 to week-12.	administered at week 12.
Primary	Tobacco reduction and abstinence	The investigators will ask about the number of cigarettes, even a puff, smoked in the past week (7-day abstinence) or use of any form of tobacco or alternative tobacco product e.g., e-cigarette or heat not burn. Salivary cotinine levels will be measured to determine abstinence from smoking.	administered at week 6.
Primary	Tobacco reduction and abstinence	The investigators will ask about the number of cigarettes, even a puff, smoked in the past week (7-day abstinence) or use of any form of tobacco or alternative tobacco product e.g., e-cigarette or heat not burn. Salivary cotinine levels will be measured to determine abstinence from smoking.	administered at week 12.
Primary	Baseline Brief Psychiatric Rating Scale (BPRS)	The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms. It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness. The score will be used to measure change between the baseline, 6-week, and 12-week time points.	Baseline interview with the participant and observations of the participant's behavior over the previous 2-3 days.
Primary	Week-6 Brief Psychiatric Rating Scale (BPRS)	The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms. It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness. The score will be used to measure change between the baseline, 6-week, and 12-week time points.	interview at week-6 with the participant and observations of the participant's behavior over the previous 2-3 days.
Primary	Week-12 Brief Psychiatric Rating Scale (BPRS)	The Semi-Structured Interview for Brief Psychiatric Rating Scale is completed by the PI or trained research staff and assesses the number and severity of psychiatric symptoms. It consists of 24 items that are rated from 1 (not present) to 7 (extremely severe), and the items are summed for a total psychopathology score, with a possible range from 24-168 and a higher score indicating a higher severity of illness. The score will be used to measure change between the baseline, 6-week, and 12-week time points.	interview at week-12 with the participant and observations of the participant's behavior over the previous 2-3 days.